GSK

Mylan launches Advair generic at 70% discount in US
Mylan launches Advair generic at 70% discount in US
Pharmaforum
Mylan
GSK
Advair
generics
Flag link:
Pharma companies clear the R&D decks in Q4
Pharma companies clear the R&D decks in Q4
Pharmaforum
R&D
GSK
Sanofi
Eli Lilly
Roche
Gilead Sciences
Flag link:
Artificial Intelligence Gaining Ground in Drug Development
Artificial Intelligence Gaining Ground in Drug Development
BioSpace
CASP
machine learning
artificial intelligence
drug development
Merck
Takeda
Atomwise
Bayer
GSK
Google DeepMind
Recursion Pharmaceuticals
Flag link:
Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19
Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19
Yahoo/Zacks.com
GSK
earnings
Flag link:
Amid R&D rejigs, GlaxoSmithKline axes 6 pipeline assets
Amid R&D rejigs, GlaxoSmithKline axes 6 pipeline assets
Fierce Biotech
GSK
R&D
Flag link:
Sales of shingles vaccine boost profits at GSK
Sales of shingles vaccine boost profits at GSK
Yahoo/Reuters
GSK
earnings
vaccines
shingles
Shingrix
Flag link:
Mylan’s Generic Advair Breathes New Life into Asthma Market
Mylan’s Generic Advair Breathes New Life into Asthma Market
Xtalks
Mylan
GSK
Advair
generics
FDA
asthma
Wixela Inhub
Flag link:
After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck
After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck
Endpoints
GSK
Merck KGaA
Tesaro
immunotherapy
Flag link:
Mylan finally crosses the finish line with long-awaited generic of GlaxoSmithKline's Advair
Mylan finally crosses the finish line with long-awaited generic of GlaxoSmithKline's Advair
Fierce Pharma
Mylan
GSK
FDA
Advair
generics
Wixela Inhub
Flag link:
CEO Emma Walmsley takes GlaxoSmithKline on a quest for identity
CEO Emma Walmsley takes GlaxoSmithKline on a quest for identity
Stat
GSK
Pharma CEOs
Emma Walmsley
Flag link:
GSK spinning out VC arm SR One
GSK spinning out VC arm SR One
BioCentury
GSK
SR One
spinoffs
venture capital
Flag link:
Last week in biopharma - earnings reports, drug pricing, a new GENE CEO and more
Last week in biopharma - earnings reports, drug pricing, a new GENE CEO and more
CP Wire
earnings
drug pricing
Genentech
Eli Lilly
Medtronic
Roche
M&A
Takeda
GSK
FDA
Flag link:
Last week in biopharma-earnings reports, drug pricing, a new GENE CEO and more
earnings
drug pricing
Genentech
Eli Lilly
Medtronic
Roche
M&A
Takeda
GSK
FDA
Flag link:
GSK closes acquisition of Tesaro for $5.1bn
GSK closes acquisition of Tesaro for $5.1bn
Pharmaceutical Business Review
GSK
Tesaro
M&A
oncology
Flag link:
GSK Chairman Sir Philip Hampton Steps Down Ahead of Company Split
GSK Chairman Sir Philip Hampton Steps Down Ahead of Company Split
BioSpace
GSK
Philip Hampton
restructuring
Flag link:
Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
Yahoo/Motley Fool
drug pricing
Big Pharma
Amgen
AstraZeneca
Pfizer
GSK
Merck
Gilead
Flag link:
Sen. Schumer curiously links Shingrix shortage to shutdown, but Glaxo says there's no connection
Sen. Schumer curiously links Shingrix shortage to shutdown, but Glaxo says there's no connection
Fierce Pharma
GSK
Shingrix
vaccines
drug shortage
government shutdown
Flag link:
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
JPMHC 2019
Merck
FDA
M&A
Celgene
Bristol-Myers Squibb
Genevant
IPOs
Eli Lilly
Novartis
GSK
Teva Pharmaceutical
Alexion
Pear Therapeutics
Flag link:
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
Biopharma Dive
Editas
CRISPR
GSK
Tesaro
Clovis Oncology
M&A
AbbVie
JPMHC 2019
Flag link:
Class Action Lawsuit Aims to Halt GSK Acquisition of Tesaro
Class Action Lawsuit Aims to Halt GSK Acquisition of Tesaro
BioSpace
GSK
M&A
Tesaro
shareholders
Flag link:

Pages